In order to accommodate the continuous growth and evolution of the peptide therapeutic market, CordenPharma Colorado completed earlier this year an expansion of its Solid-Phase Peptide Synthesis manufacturing capacity with the addition of an extra-large 3000 L SPPS vessel. The company is anticipating expanding U.S. market needs by investing in new manufacturing techniques to improve the productivity of its peptide assets—in particular via the deployment of innovative Process Analytical Technolog...